Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16407345 | 0.99 | APP (0.52) | APPNR4A2PKMLMNADHFR | |
| SCHEMBL16407134 | 0.93 | APP (0.54) | APPNR4A2PKMLMNADHFR | |
| SCHEMBL16407161 | 0.92 | LMNA (0.57) | APPNR4A2PKMLMNADHFR | |
| SCHEMBL16407072 | 0.91 | RAD52 (0.51) | APPNR4A2PKMLMNADHFR | |
| SCHEMBL16407051 | 0.91 | APP (0.54) | APPNR4A2PKMLMNADHFR | |
| SCHEMBL16405617 | 0.91 | HRH3 (0.51) | APPPKMDHFRHRH3BACE1 | |
| SCHEMBL16407149 | 0.90 | ACHE (0.53) | APPNR4A2PKMHRH3BACE1 | |
| SCHEMBL16405599 | 0.90 | RAD52 (0.52) | APPPKMDHFRHRH3BACE1 | |
| SCHEMBL16407349 | 0.89 | ACHE (0.54) | APPNR4A2PKMHRH3BACE1 | |
| SCHEMBL16407135 | 0.86 | CYP2D6 (0.57) | APPNR4A2DHFRHRH3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008418-A1 | Aminoquinoline Derivatives and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| US-11026943-B2 | Aminoquinoline derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2021-06-08 | — | — | US | disclosed |
| US-20170209441-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | UNIVERSITY OF DELHI (IN) | 2017-07-27 | — | — | US | disclosed |
| US-9567316-B2 | Aminoquinoline derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150023930-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023930-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | LRRK2, NLN, AADAT | APP 219/4885NR4A2 876/4885PKM 2102/4885 |
| US-20220008418-A1 | Aminoquinoline Derivatives and Uses Thereof | LRRK2, NLN, AADAT | APP 219/4885NR4A2 876/4885PKM 2102/4885 |
| US-11026943-B2 | Aminoquinoline derivatives and uses thereof | LRRK2, NLRP3, AADAT | APP 256/4885NR4A2 1253/4885PKM 2112/4885 |
| US-20170209441-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | LRRK2, NLRP3, AADAT | APP 256/4885NR4A2 1253/4885PKM 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.